THE EXPRESSION OF p53 AND p16 IN LOW GRADE AND HIGH GRADE SEROUS CARCINOMA OF OVARY
Keywords:
Ovarian serous carcinoma, p53, p16Abstract
Background Ovarian serous carcinoma is a common ovarian epithelial malignancy,
divided into low grade serous carcinoma (LGSC) and high grade serous carcinoma
(HGSC). HGSC accounts for 60-80% of ovarian carcinomas and is the most aggressive
type and has a poor prognosis. The literature has described various genetic mutations
involved in the occurrence of HGSC, one of which is p53 and p16 mutations. Diagnostic
and prognostic value of LGSC and HGSC related to its targeted therapy.
Objective This study aimed to analyze the differences in the expression of p53 and p16
in LGSC and HGSC at anatomical pathology of laboratory dr. Kariadi Hospital.
Methods : This study was an observational analytic study with a cross sectional design
involving 65 patients with ovarian serous carcinoma diagnosed between January 2017
and December 2021. The data collected were age, LGSC and HGSC subtypes as well
as p53 and p16 expressions were obseved by a pathologists and a resident. Compatibility
between observers were tested using Kappa test. Data analysis used Chi square test and
Fisher's exact test.
Results This study included 65 patients aged between 30-68 years, consist of 50 patients
with HGSC and 15 patients with LGSC (P <0,001). Kappa test results between two
observers showed a score of k = 0,88.
Conclusion There is a significant difference between the expression of p53 and p16 in
HGSC, as the expression of p53 and p16 is much stronger and diffuse in high grade
serous carcinoma compared to LGSC.
References
Kobel M, Kalloger SE, Lee S, Duggan MA, Kalemen LE, Prentise L, et al. -Biomarkerbased Ovarian Carcinoma typing : A Histological Investigation in the Ovarian Tumor
Analysis Consortium. 2013 October, 22(10):1677-86
Lax SF, Cheung An, Oliva E. WHO Classification of Tumours of Female. 5 edition.
, 31-45.
Kumar V, Abbas A.K, Aster, J.C. Robbins and Cotran Pathologic Basis of Disease.
th ed. Philadelphia: Elsevier; 2015.
Yemelyanova A, Vang R, Kshirsagar M, Lu D, Marks M, Shih L, Kurman R.
Immunohistochemical staining patterns of p53 can serve as a surrogate marker for
TP53 mutations in ovarian carcinoma : an immunohistochemical and nucleotide
sequencing analysis. Mod Pathol 2011 March, 10(24) : 1248-53.
Manu V, Tin Aung Hein, Boruah D, Srinivas V. Serous ovarian tumors :
Immunohistochemical profiling as an aid to grading and understanding tumorigenesis.
Med J Armed Forces India. 2020 Jan, 76(1):30-36.
Luis F, Liliana A, Susana R et. al. WT1, p53 and p16 expression in the diagnosis of
low and high grade serous ovarian carcinomas and their
relation to prognosis. Oncotarget. 2018. Feb 19, 9(22): 15818-27.
Robboy SJ, Mutter GL, Pratt J. Robboy’s Pathology of Female Reproductive Tracts.
Elsevier. 2014, 608-617
Jie li, Oluwole Fadarre, Li Xiang, Beihua Kong, Wenxin Zheng. Ovarian serous
carcinoma recent concepts on its origin and carcinogenesis. China: Journal of
hematology and oncology; 2012, 5(1) : 8
Freddie B et.al. Global Cancer Statistic 2018 : GLOBOCAN estimates of incidence
and mortality worldwide for 36 cancer in 185 countries. ACS Journal. A cancer journal
for clinicians; 2018, 68(6).
Asmuddin. Peran Gen p16 pada siklus sel terhadap pembentukan kanker. 2011
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Oceana Biomedicina Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
